Castle Biosciences Inc
NASDAQ:CSTL
Market Cap (Intraday) | 1.32B |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | N/A |
50-Day MA | N/A |
200-Day MA | N/A |
Castle Biosciences, Inc. Stock, NASDAQ:CSTL
820 South Friendswood Drive, Suite 201, Friendswood, Texas 77546
United States of America
Phone: +1.866.788.9007
Number of Employees: 133
Description
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.